The EMCDDA reports on high availability and potency of substances, increasingly sophisticated supply infrastructures and the involvement and exploitation of people in situations of vulnerability in informal markets.
TEDI find consistent adulteration and risk trends across Europe's drug market since 2018, and call for more resources to improve market monitoring and harm reduction.
AIDS 2024 will convene thousands of people living with, affected by and working on HIV to share knowledge, best practices and lessons from the HIV response.
IDPC, Viso Mutop and GDPO explore the report's discussion of buoyant drug markets and UNODC's stance on key issues like decriminalisation, human rights and environmental impact, noting the growing influence of green criminology and its potential to reshape perspectives.
Van Amsterdam et al. present the first set of empirical findings relating to generic drug legislation in the UK and Germany, revealing it to be largely ineffective in counteracting NPS use and causing increased public health problems.
Harm Reduction International expose the large sums of aid being spent on drug prohibition worldwide, calling on governments and donors to divest from punitive policies and invest in health and human rights.
Huge amounts of aid have been spent on fuelling drug prohibition in lower-income countries, causing significant harm to vulnerable communities while defaulting on stated supply-reduction goals.
ICEERS estimates global lifetime ayahuasca use at above four million and notes that no media-reported deaths have been corroborated by forensic analysis.
Van Selm et al. highlight the considerable lack of data regarding migrants who use drugs and their access to drug dependency services, with 15 recommendations designed to improve data collection and service accessibility and availability,
